NASDAQ:LPCN - Lipocine Stock Price, Forecast & News

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Lipocine Inc (NASDAQ:LPCN) released its quarterly earnings data on Tuesday, November, 12th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.04. The specialty pharmaceutical company had revenue of $0.17 million for the quarter. View Lipocine's Earnings History.

Lipocine is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Lipocine.

2 Wall Street analysts have issued twelve-month target prices for Lipocine's stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Lipocine's share price to reach $2.00 in the next year. This suggests a possible upside of 277.4% from the stock's current price. View Analyst Price Targets for Lipocine.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lipocine.

Media stories about LPCN stock have trended very negative this week, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Lipocine earned a daily sentiment score of -3.8 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Lipocine.

Some companies that are related to Lipocine include DiaMedica Therapeutics (DMAC), resTORbio (TORC), Hoth Therapeutics (HOTH), Vascular Biogenics (VBLT), SUMMIT THERAPEU/S (SMMT), Adamis Pharmaceuticals (ADMP), Q BioMed (QBIO), Zafgen (ZFGN), Forward Pharma A/S (FWP), IntelGenx Technologies (IGXT), PLx Pharma (PLXP), Acer Therapeutics (ACER), Moleculin Biotech (MBRX), Humanigen (HGEN) and Soligenix (SNGX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Novavax (NVAX), Cara Therapeutics (CARA), Melinta Therapeutics (MLNT), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Actinium Pharmaceuticals (ATNM), Protalix Biotherapeutics (PLX) and Cypress Semiconductor (CY).

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LPCN stock can currently be purchased for approximately $0.53.

Lipocine has a market capitalization of $13.46 million and generates $430,000.00 in revenue each year. The specialty pharmaceutical company earns $-11,660,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Lipocine employs 10 workers across the globe.View Additional Information About Lipocine.

The official website for Lipocine is http://www.lipocine.com/.

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]